Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

16 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Screening Visit 1 Psoriasis NCT02695940

- 27-09-21 - 1 Formulier, 10 Itemgroepen, 62 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Eligibility criteria, Demography, Medical History, Treated body regions, Vital signs, ECG, Blood sample, Urine sample, miscellaneous
NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Eligibility NCT00408187 Psoriasis - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 30 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00408187

Eligibility NCT00606450 Psoriasis - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 24 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00606450

Eligibility NCT00852670 Plaque Psoriasis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 7 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00852670

Eligibility NCT00245765 Chronic Plaque Psoriasis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 12 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00245765

Eligibility NCT00574249 Chronic Plaque Psoriasis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00574249

Eligibility NCT00329303 Psoriasis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00329303

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

- 15-06-21 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01316224

Visit 6 Psoriasis NCT02695940

- 22-01-18 - 1 Formulier, 8 Itemgroepen, 50 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Medical History and physical exam, Vital signs, ECG, Blood sample, Urine sample, Picture, Signature
NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Visit 7 Psoriasis NCT02695940

- 22-01-18 - 1 Formulier, 3 Itemgroepen, 7 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Medical History and Physical Examination, signature
NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Visit 4 Psoriasis NCT02695940

- 22-01-18 - 1 Formulier, 4 Itemgroepen, 22 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Medical History and Physical examination, Medication, signature
NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Visit 5 Psoriasis NCT02695940

- 22-01-18 - 1 Formulier, 4 Itemgroepen, 25 Data-elementen, 1 Taal
Itemgroepen: Administrative data, Medical History, Medication, signature
NCT02695940 A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis. Quelle: Prof. Dr. Dr. h.c. Thomas Luger University Hospital of Muenster Department of Dermatology

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial